These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 33183110)
1. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Liang H; Du J; Elhassan RM; Hou X; Fang H Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110 [No Abstract] [Full Text] [Related]
2. CDK7 inhibitors as anticancer drugs. Sava GP; Fan H; Coombes RC; Buluwela L; Ali S Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714 [TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 7 inhibitors in cancer therapy. Wang M; Wang T; Zhang X; Wu X; Jiang S Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930 [TBL] [Abstract][Full Text] [Related]
4. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022). Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020 [TBL] [Abstract][Full Text] [Related]
5. CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? Diab S; Yu M; Wang S J Med Chem; 2020 Jul; 63(14):7458-7474. PubMed ID: 32150405 [TBL] [Abstract][Full Text] [Related]
6. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Fisher RP Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763 [TBL] [Abstract][Full Text] [Related]
7. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7. Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851 [TBL] [Abstract][Full Text] [Related]
8. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632 [TBL] [Abstract][Full Text] [Related]
9. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7). Ji W; Du G; Jiang J; Lu W; Mills CE; Yuan L; Jiang F; He Z; Bradshaw GA; Chung M; Jiang Z; Byun WS; Hinshaw SM; Zhang T; Gray NS Eur J Med Chem; 2024 Oct; 276():116613. PubMed ID: 39004018 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of cyclin-dependent kinase 7 inhibitors. Teng Y; Lu K; Zhang Q; Zhao L; Huang Y; Ingarra AM; Galons H; Li T; Cui S; Yu P; Oumata N Eur J Med Chem; 2019 Dec; 183():111641. PubMed ID: 31514062 [TBL] [Abstract][Full Text] [Related]
11. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587 [TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer. Choi YJ; Lee H; Kim DS; Kim DH; Kang MH; Cho YH; Choi CM; Yoo J; Lee KO; Choi EK; Lee JC; Rho JK Eur J Pharmacol; 2021 Sep; 907():174298. PubMed ID: 34224696 [TBL] [Abstract][Full Text] [Related]
13. TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters. Webb BM; Bryson BL; Williams-Medina E; Bobbitt JR; Seachrist DD; Anstine LJ; Keri RA J Biol Chem; 2021 Oct; 297(4):101162. PubMed ID: 34481843 [TBL] [Abstract][Full Text] [Related]
14. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334 [TBL] [Abstract][Full Text] [Related]
15. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer. Attia YM; Shouman SA; Salama SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340192 [TBL] [Abstract][Full Text] [Related]
16. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. Wang BY; Liu QY; Cao J; Chen JW; Liu ZS Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010 [TBL] [Abstract][Full Text] [Related]
17. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists. Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587 [TBL] [Abstract][Full Text] [Related]
18. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs? Lolli G; Johnson LN Cell Cycle; 2005 Apr; 4(4):572-7. PubMed ID: 15876871 [TBL] [Abstract][Full Text] [Related]
19. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours. Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines. Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK Cells; 2020 Dec; 9(12):. PubMed ID: 33287368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]